A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML-Reference-Cited by-同舟云学术

A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML

Published:2020-10-23 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Ambinder Alexander J.,Norsworthy Kelly,Hernandez Daniela,Palau Laura,Paun Bogdan,Duffield Amy,Chandraratna Rosh,Sanders Martin,Varadhan Ravi,Jones Richard J.,Douglas Smith B.,Ghiaur Gabriel

Funder

National Heart, Lung, and Blood Institute

National Cancer Institute

Leukemia and Lymphoma Society

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference31 articles.

1. Retinoic acid receptors, hematopoiesis and leukemogenesis;Collins;Curr Opin Hematol,2008

2. Acute promyelocytic leukemia: From highly fatal to highly curable;Wang;Blood,2008

3. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia;Boutzen;J Exp Med,2016

4. Superenhancer analysis defi nes novel epigenomic subtypes of non-APL AML, including an RARα dependency targetable by SY-1425, a potent and selective RARα agonist;McKeown;Cancer Discovery,2017

5. Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy;Mugoni;Cell Res,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction and Demonstration of Retinoic Acid Receptor Agonist Ch55 as an Antifibrotic Agent in the Dermis;Journal of Investigative Dermatology;2023-09

2. The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away;Cancers;2023-07-08

3. Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid;Cancers;2021-04-29